Ignite Creation Date:
2024-05-06 @ 2:01 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04182516
Status:
TERMINATED
Last Update Posted:
2024-04-22
First Post:
2019-11-12
Brief Title:
Study of NMS-03305293 in Pts with Selected AdvancedMetastatic Solid Tumors
Sponsor:
Nerviano Medical Sciences
Organization:
Nerviano Medical Sciences
Study Overview
Official Title:
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected AdvancedMetastatic Solid Tumors
Status:
TERMINATED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I first-in-human open-label multicenter dose-escalation and dose expansion study with the aim of exploring safety tolerability and preliminary antitumor activity of NMS-03305293 a PARP inhibitor as single agent in adult patients with selected advancedmetastatic relapsedrefractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-003918-40 | EUDRACT_NUMBER | None | None |